Qurient Demonstrates Efficacy and Safety of Mocaciclib Phase 1 Across Breast, Prostate and Pancreatic Cancers
Predicted impact: Low
Phase 1 data already reported via ESMO unveiling within the last 14 days; no new size.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.